Review
Waldenström macroglobulinaemia: the key questions
Anita D'Souza,
Stephen Ansell,
Craig Reeder,
Morie A. Gertz,
Anita D'Souza
Division of Hematology, Mayo Clinic, Rochester, MN, USA
Search for more papers by this authorStephen Ansell
Division of Hematology, Mayo Clinic, Rochester, MN, USA
Search for more papers by this authorCraig Reeder
Division of Hematology/Oncology, Mayo Clinic, Scottsdale, AZ, USA
Search for more papers by this authorCorresponding Author
Morie A. Gertz
Division of Hematology, Mayo Clinic, Rochester, MN, USA
Correspondence: Morie A. Gertz, Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA.
E-mail: [email protected]
Search for more papers by this authorAnita D'Souza,
Stephen Ansell,
Craig Reeder,
Morie A. Gertz,
Anita D'Souza
Division of Hematology, Mayo Clinic, Rochester, MN, USA
Search for more papers by this authorStephen Ansell
Division of Hematology, Mayo Clinic, Rochester, MN, USA
Search for more papers by this authorCraig Reeder
Division of Hematology/Oncology, Mayo Clinic, Scottsdale, AZ, USA
Search for more papers by this authorCorresponding Author
Morie A. Gertz
Division of Hematology, Mayo Clinic, Rochester, MN, USA
Correspondence: Morie A. Gertz, Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA.
E-mail: [email protected]
Search for more papers by this authorSummary
In this review, the key issues that pertain to Waldenström disease are discussed in a concise question-and-answer format. Diagnosis, prognosis, and indications for state-of-the-art therapy are updated. Current therapies presented at the 7th International Workshop for Waldenström Macroglobulinaemia are included.
References
- Ansell, S.M., Kyle, R.A., Reeder, C.B., Fonseca, R., Mikhael, J.R., Morice, W.G., Bergsagel, P.L., Buadi, F.K., Colgan, J.P., Dingli, D., Dispenzieri, A., Greipp, P.R., Habermann, T.M., Hayman, S.R., Inwards, D.J., Johnston, P.B., Kumar, S.K., Lacy, M.Q., Lust, J.A., Markovic, S.N., Micallef, I.N., Nowakowski, G.S., Porrata, L.F., Roy, V., Russell, S.J., Short, K.E., Stewart, A.K., Thompson, C.A., Witzig, T.E., Zeldenrust, S.R., Dalton, R.J., Rajkumar, S.V. & Gertz, M.A. (2010) Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines. Mayo Clinic Proceedings, 85, 824–833.
- Bachanova, V. & Burns, L.J. (2012) Hematopoietic cell transplantation for Waldenström macroglobulinemia. Bone Marrow Transplantation, 47, 330–336.
- Berentsen, S. (2007) Rituximab for the treatment of autoimmune cytopenias. Haematologica, 92, 1589–1596.
- Berentsen, S., Randen, U., Vagan, A.M., Hjorth-Hansen, H., Vik, A., Dalgaard, J., Jacobsen, E.M., Thoresen, A.S., Beiske, K. & Tjonnfjord, G.E. (2010) High response rate and durable remissions following fludarabine and rituximab combination therapy for chronic cold agglutinin disease. Blood, 116, 3180–3184.
- Buske, C., Hoster, E., Dreyling, M., Eimermacher, H., Wandt, H., Metzner, B., Fuchs, R., Bittenbring, J., Woermann, B., Hohloch, K., Hess, G., Ludwig, W.D., Schimke, J., Schmitz, S., Kneba, M., Reiser, M., Graeven, U., Klapper, W., Unterhalt, M., Hiddemann, W. & German Low-Grade Lymphoma Study Group. (2009) The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). Leukemia, 23, 153–161.
- Chang, H., Qi, C., Trieu, Y., Jiang, A., Young, K.H., Chesney, A., Jani, P., Wang, C., Reece, D. & Chen, C. (2009) Prognostic relevance of 6q deletion in Waldenström's macroglobulinemia: a multicenter study. Clinical Lymphoma & Myeloma, 9, 36–38.
- Chen, C., Kouroukis, C.T., White, D., Voralia, M., Stadtmauer, E., Stewart, A.K., Wright, J.J., Powers, J., Walsh, W. & Eisenhauer, E. (2009) Bortezomib in relapsed or refractory Waldenström's macroglobulinemia. Clinical Lymphoma & Myeloma, 9, 74–76.
- Cohen, A.D., Zhou, P., Xiao, Q., Fleisher, M., Kalakonda, N., Akhurst, T., Chitale, D.A., Moscowitz, C., Dhodapkar, M.V., Teruya-Feldstein, J., Filippa, D. & Comenzo, R.L. (2004) Systemic AL amyloidosis due to non-Hodgkin's lymphoma: an unusual clinicopathologic association. British Journal of Haematology, 124, 309–314.
- Dhodapkar, M.V., Hoering, A., Gertz, M.A., Rivkin, S., Szymonifka, J., Crowley, J. & Barlogie, B. (2009) Long-term survival in Waldenström macroglobulinemia: 10-year follow-up of Southwest Oncology Group-directed intergroup trial S9003. Blood, 113, 793–796.
- Dimopoulos, M.A., Kantarjian, H., Estey, E., O'Brien, S., Delasalle, K., Keating, M.J., Freireich, E.J. & Alexanian, R. (1993) Treatment of Waldenström macroglobulinemia with 2-chlorodeoxyadenosine. Annals of Internal Medicine, 118, 195–198.
- Dimopoulos, M.A., Anagnostopoulos, A., Kyrtsonis, M.C., Zervas, K., Tsatalas, C., Kokkinis, G., Repoussis, P., Symeonidis, A., Delimpasi, S., Katodritou, E., Vervessou, E., Michali, E., Pouli, A., Gika, D., Vassou, A., Terpos, E., Anagnostopoulos, N., Economopoulos, T. & Pangalis, G. (2007) Primary treatment of Waldenström macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. Journal of Clinical Oncology, 25, 3344–3349.
- Elsawa, S.F., Novak, A.J., Ziesmer, S.C., Almada, L.L., Hodge, L.S., Grote, D.M., Witzig, T.E., Fernandez-Zapico, M.E. & Ansell, S.M. (2011) Comprehensive analysis of tumor microenvironment cytokines in Waldenström macroglobulinemia identifies CCL5 as a novel modulator of IL-6 activity. Blood, 118, 5540–5549.
- Figueroa, J.J., Bosch, E.P., Dyck, P.J., Singer, W., Vrana, J.A., Theis, J.D., Dogan, A. & Klein, C.J. (2012) Amyloid-like IgM deposition neuropathy: a distinct clinico-pathologic and proteomic profiled disorder. Journal of the Peripheral Nervous System, 17, 182–190.
- Foran, J.M., Rohatiner, A.Z., Coiffier, B., Barbui, T., Johnson, S.A., Hiddemann, W., Radford, J.A., Norton, A.J., Tollerfield, S.M., Wilson, M.P. & Lister, T.A. (1999) Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenström's macroglobulinemia, and mantle-cell lymphoma. Journal of Clinical Oncology, 17, 546–553.
- Gachard, N., Parrens, M., Soubeyran, I., Petit, B., Marfak, A., Rizzo, D., Devesa, M., Delage-Corre, M., Coste, V., Laforet, M.P., de Mascarel, A., Merlio, J.P., Bouabdhalla, K., Milpied, N., Soubeyran, P., Schmitt, A., Bordessoule, D., Cogne, M. & Feuillard, J. (2013) IGHV gene features and MYD88 L265P mutation separate the three marginal zone lymphoma entities and Waldenström macroglobulinemia/lymphoplasmacytic lymphomas. Leukemia, 27, 183–189.
- Gertz, M.A. (2012) Baby, it's cold outside!. Blood, 119, 5943–5944.
- Gertz, M.A., Kyle, R.A. & Noel, P. (1993) Primary systemic amyloidosis: a rare complication of immunoglobulin M monoclonal gammopathies and Waldenström's macroglobulinemia. Journal of Clinical Oncology, 11, 914–920.
- Gertz, M.A., Rue, M., Blood, E., Kaminer, L.S., Vesole, D.H. & Greipp, P.R. (2004) Multicenter phase 2 trial of rituximab for Waldenström macroglobulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98). Leukemia & Lymphoma, 45, 2047–2055.
- Gertz, M.A., Abonour, R., Heffner, L.T., Greipp, P.R., Uno, H. & Rajkumar, S.V. (2009) Clinical value of minor responses after 4 doses of rituximab in Waldenström macroglobulinaemia: a follow-up of the Eastern Cooperative Oncology Group E3A98 trial. British Journal of Haematology, 147, 677–680, Epub 2009 Sep 14.
- Gertz, M.A., Buadi, F.K. & Hayman, S.R. (2011) IgM amyloidosis: clinical features in therapeutic outcomes. Clinical Lymphoma, Myeloma & Leukemia, 11, 146–148.
- Ghobrial, I.M. (2012) Are you sure this is Waldenstrom macroglobulinemia? American Society of Hematology Education Book, 2012, 586–594.
- Ghobrial, I.M., Fonseca, R., Greipp, P.R., Blood, E., Rue, M., Vesole, D.H., Gertz, M.A. & Eastern Cooperative Oncology Group. (2004) Initial immunoglobulin M ‘flare’ after rituximab therapy in patients diagnosed with Waldenström macroglobulinemia: an Eastern Cooperative Oncology Group Study. Cancer, 101, 2593–2598.
- Ghobrial, I.M., Xie, W., Padmanabhan, S., Badros, A., Rourke, M., Leduc, R., Chuma, S., Kunsman, J., Warren, D., Poon, T., Harris, B., Sam, A., Anderson, K.C., Richardson, P.G., Treon, S.P., Weller, E. & Matous, J. (2010a) Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia. American Journal of Hematology, 85, 670–674.
- Ghobrial, I.M., Hong, F., Padmanabhan, S., Badros, A., Rourke, M., Leduc, R., Chuma, S., Kunsman, J., Warren, D., Harris, B., Sam, A., Anderson, K.C., Richardson, P.G., Treon, S.P., Weller, E. & Matous, J. (2010b) Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenström macroglobulinemia. Journal of Clinical Oncology, 28, 1422–1428.
- Ghobrial, I.M., Gertz, M., Laplant, B., Camoriano, J., Hayman, S., Lacy, M., Chuma, S., Harris, B., Leduc, R., Rourke, M., Ansell, S.M., Deangelo, D., Dispenzieri, A., Bergsagel, L., Reeder, C., Anderson, K.C., Richardson, P.G., Treon, S.P. & Witzig, T.E. (2010c) Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenström macroglobulinemia. Journal of Clinical Oncology, 28, 1408–1414.
- Ghobrial, I.M., Roccaro, A., Hong, F., Weller, E., Rubin, N., Leduc, R., Rourke, M., Chuma, S., Sacco, A., Jia, X., Azab, F., Azab, A.K., Rodig, S., Warren, D., Harris, B., Varticovski, L., Sportelli, P., Leleu, X., Anderson, K.C. & Richardson, P.G. (2010d) Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenström's macroglobulinemia. Clinical Cancer Research, 16, 1033–1041.
- Ghobrial, I.M., Poon, T., Rourke, M., Chuma, S., Kunsman, J., Banwait, R., Sam, A., Warren, D., Anderson, K., Richardson, P., Treon, S. & Matous, J. (2010e) Phase II trial of single agent panobinostat (LBH589) in relapsed or relapsed/refractory Waldenström macroglobulinemia abstract. Blood (ASH Annual Meeting Abstracts), 116, 3952.
- Ghobrial, I.M., Moreau, P., Harris, B., Poon, T., Jourdan, E., Maisonneuve, H., Benhadji, K.A., Hossain, A.M., Nguyen, T.S., Wooldridge, J.E. & Leblond, V. (2012) A multicenter phase II study of single-agent enzastaurin in previously treated Waldenström macroglobulinemia. Clinical Cancer Research, 18, 5043–5050.
- Hodge, L.S. & Ansell, S.M. (2011) Jak/Stat pathway in Waldenström's macroglobulinemia. Clinical Lymphoma, Myeloma & Leukemia, 11, 112–114.
- Hultcrantz, M.L., Pfeiffer, R.M., Bjorkholm, M., Goldin, L., Turesson, I., Schulman, S., Landgren, O. & Kristinsson, S.Y. (2012) Elevated risk of venous but not arterial thrombosis in Waldenström's macroglobulinemia and lymphoplasmacytic lymphoma [abstract]. Blood (ASH Annual Meeting Abstracts), 120, 1603.
- Hunter, Z.R., Manning, R.J., Hanzis, C., Ciccarelli, B.T., Ioakimidis, L., Patterson, C.J., Lewicki, M.C., Tseng, H., Gong, P., Liu, X., Zhou, Y., Yang, G., Sun, J., Xu, L., Sheehy, P., Morra, M. & Treon, S.P. (2010) IgA and IgG hypogammaglobulinemia in Waldenström's macroglobulinemia. Haematologica, 95, 470–475.
- Issa, G.C., Leblebjian, H., Roccaro, A.M. & Ghobrial, I.M. (2011a) New insights into the pathogenesis and treatment of Waldenström macroglobulinemia. Current Opinion in Hematology, 18, 260–265.
- Issa, G.C., Ghobrial, I.M. & Roccaro, A.M. (2011b) Novel agents in Waldenström macroglobulinemia. Clinical Investigation (London), 1, 815–824.
- Kastritis, E., Kyrtsonis, M.C., Hadjiharissi, E., Symeonidis, A., Michalis, E., Repoussis, P., Tsatalas, C., Michael, M., Sioni, A., Kartasis, Z., Stefanoudaki, E., Voulgarelis, M., Delimpasi, S., Gavriatopoulou, M., Koulieris, E., Gika, D., Zomas, A., Roussou, P., Anagnostopoulos, N., Economopoulos, T., Terpos, E., Zervas, K., Dimopoulos, M.A. & Greek Myeloma Study Group. (2010) Validation of the International Prognostic Scoring System (IPSS) for Waldenström's macroglobulinemia (WM) and the importance of serum lactate dehydrogenase (LDH). Leukemia Research, 34, 1340–1343.
- Klein, C.J., Moon, J.S., Mauermann, M.L., Zeldenrust, S.R., Wu, Y., Dispenzieri, A. & Dyck, P.J. (2011) The neuropathies of Waldenström's macroglobulinemia (WM) and IgM-MGUS. The Canadian Journal of Neurological Sciences, 38, 289–295.
- Kristinsson, S.Y., Bjorkholm, M., Goldin, L.R., McMaster, M.L., Turesson, I. & Landgren, O. (2008) Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia patients: a population-based study in Sweden. Blood, 112, 3052–3056.
- Kyle, R.A., Greipp, P.R., Gertz, M.A., Witzig, T.E., Lust, J.A., Lacy, M.Q. & Therneau, T.M. (2000) Waldenström's macroglobulinaemia: a prospective study comparing daily with intermittent oral chlorambucil. British Journal of Haematology, 108, 737–742.
- Kyle, R.A., Therneau, T.M., Rajkumar, S.V., Remstein, E.D., Offord, J.R., Larson, D.R., Plevak, M.F. & Melton, L.J. 3rd (2003a) Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Blood, 102, 3759–3764.
- Kyle, R.A., Treon, S.P., Alexanian, R., Barlogie, B., Bjorkholm, M., Dhodapkar, M., Lister, T.A., Merlini, G., Morel, P., Stone, M., Branagan, A.R. & Leblond, V. (2003b) Prognostic markers and criteria to initiate therapy in Waldenström's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenström's Macroglobulinemia. Seminars in Oncology, 30, 116–120.
- Kyriakou, C., Canals, C., Sibon, D., Cahn, J.Y., Kazmi, M., Arcese, W., Kolbe, K., Gorin, N.C., Thomson, K., Milpied, N., Niederwieser, D., Indrak, K., Corradini, P., Sureda, A. & Schmitz, N. (2010) High-dose therapy and autologous stem-cell transplantation in Waldenström macroglobulinemia: the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Journal of Clinical Oncology, 28, 2227–2232.
- Landgren, O. & Staudt, L. (2012) MYD88 L265P somatic mutation in IgM MGUS. New England Journal of Medicine, 367, 2255–2256.
- Laszlo, D., Andreola, G., Rigacci, L., Fabbri, A., Rabascio, C., Mancuso, P., Pruneri, G., Radice, D., Pinto, A., Frigeri, F., Calabrese, L., Billio, A., Bertolini, F. & Martinelli, G. (2010) Rituximab and subcutaneous 2-chloro-2′-deoxyadenosine combination treatment for patients with Waldenström macroglobulinemia: clinical and biologic results of a phase II multicenter study. Journal of Clinical Oncology, 28, 2233–2238.
- Leblond, V., Johnson, S., Chevret, S., Copplestone, A., Rule, S., Tournilhac, O., Seymour, J.F., Patmore, R.D., Wright, D., Morel, P., Dilhuydy, M.S., Willoughby, S., Dartigeas, C., Malphettes, M., Royer, B., Ewings, M., Pratt, G., Lejeune, J., Nguyen-Khac, F., Choquet, S. & Owen, R.G. (2013) Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenström macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma. Journal of Clinical Oncology, 31, 301–307.
- Leleu, X., Soumerai, J., Roccaro, A., Hatjiharissi, E., Hunter, Z.R., Manning, R., Ciccarelli, B.T., Sacco, A., Ioakimidis, L., Adamia, S., Moreau, A.S., Patterson, C.J., Ghobrial, I.M. & Treon, S.P. (2009) Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs. Journal of Clinical Oncology, 27, 250–255.
- Lopate, G., Pestronk, A., Al-Lozi, M., Lynch, T., Florence, J., Miller, T., Levine, T., Rampy, T., Beson, B. & Ramneantu, I. (2006) Peripheral neuropathy in an outpatient cohort of patients with Sjogren's syndrome. Muscle and Nerve, 33, 672–676.
- Ly, K.I., Hochberg, E.P. & Hochberg, F.H. 2012. The Bing-Neel Syndrome: clinical observations on nine new cases and the literature. Paper presented at: International Workshops on Waldenström's Macroglobulinemia. 7th International Workshop on Waldenström's Macroglobulinemia and Symposium on Advances in Multiple Myeloma; 2012 Aug 23–26; Newport, RI.
- Morel, P., Duhamel, A., Gobbi, P., Dimopoulos, M.A., Dhodapkar, M.V., McCoy, J., Crowley, J., Ocio, E.M., Garcia-Sanz, R., Treon, S.P., Leblond, V., Kyle, R.A., Barlogie, B. & Merlini, G. (2009) International prognostic scoring system for Waldenström macroglobulinemia. Blood, 113, 4163–4170.
- Nguyen-Khac, F., Lambert, J., Chapiro, E., Grelier, A., Mould, S., Barin, C., Daudignon, A., Gachard, N., Struski, S., Henry, C., Penther, D., Mossafa, H., Andrieux, J., Eclache, V., Bilhou-Nabera, C., Luquet, I., Terre, C., Baranger, L., Mugneret, F., Chiesa, J., Mozziconacci, M.J., Callet-Bauchu, E., Veronese, L., Blons, H., Owen, R., Lejeune, J., Chevret, S., Merle-Beral, H. & Leblond, V. (2012) Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenström macroglobulinemia. Haematologica, 98, 649–654.
- Owen, R.G., Treon, S.P., Al-Katib, A., Fonseca, R., Greipp, P.R., McMaster, M.L., Morra, E., Pangalis, G.A., San Miguel, J.F., Branagan, A.R. & Dimopoulos, M.A. (2003) Clinicopathological definition of Waldenström's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenström's Macroglobulinemia. Seminars in Oncology, 30, 110–115.
- Owen, R.G., Kyle, R.A., Stone, M.J., Rawstron, A.C., Leblond, V., Merlini, G., Garcia-Sanz, R., Ocio, E.M., Morra, E., Morel, P., Anderson, K.C., Patterson, C.J., Munshi, N.C., Tedeschi, A., Joshua, D.E., Kastritis, E., Terpos, E., Ghobrial, I.M., Leleu, X., Gertz, M.A., Ansell, S.M., Morice, W.G., Kimby, E. & Treon, S.P. (2013) Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop. British Journal of Haematology, 160, 171–176.
- Palladini, G., Russo, P., Bosoni, T., Sarais, G., Lavatelli, F., Foli, A., Bragotti, L.Z., Perfetti, V., Obici, L., Bergesio, F., Albertini, R., Moratti, R. & Merlini, G. (2009) AL amyloidosis associated with IgM monoclonal protein: a distinct clinical entity. Clinical Lymphoma & Myeloma, 9, 80–83.
- Rummel, M.J., Lerchenmuller, C., Greil, R., Gorner, M., Hensel, M., Engel, E., Jaeger, U., Breuer, F., Hertenstein, B., Prummer, O., Buske, C., Barth, J., Burchardt, A.C. & Brugger, W. (2012) Bendamustin-rituximab induction followed by observation or rituximab maintenance for newly diagnosed patients with Waldenström's macroglobulinemia: results from a prospective, randomized, multicenter study (StiL NHL 7–2008–MAINTAIN-; ClinicalTrials.gov Identifier: NCT00877214). Blood(ASH Annual Meeting Abstracts), 120, 2739.
- Stone, M.J. (2011) Pathogenesis and morbidity of autoantibody syndromes in Waldenström's macroglobulinemia. Clinical Lymphoma, Myeloma & Leukemia, 11, 157–159.
- Stone, M.J. & Bogen, S.A. (2012) Evidence-based focused review of management of hyperviscosity syndrome. Blood, 119, 2205–2208.
- S.H. Swerdlow, E. Campo, N.L. Harris, E.S. Jaffe, S.A. Pileri, H. Stein, J. Thiele & J.W. Vardiman (eds). (2008) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC, Lyon.
- Tedeschi, A., Benevolo, G., Varettoni, M., Battista, M.L., Zinzani, P.L., Visco, C., Meneghini, V., Pioltelli, P., Sacchi, S., Ricci, F., Nichelatti, M., Zaja, F., Lazzarino, M., Vitolo, U. & Morra, E. (2012) Fludarabine plus cyclophosphamide and rituximab in Waldenström macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced disease. Cancer, 118, 434–443.
- Telio, D., Bailey, D., Chen, C., Crump, M., Reece, D. & Kukreti, V. (2010) Two distinct syndromes of lymphoma-associated AL amyloidosis: a case series and review of the literature. American Journal of Hematology, 85, 805–808.
- Treon, S.P. (2009) How I treat Waldenström macroglobulinemia. Blood, 114, 2375–2385.
- Treon, S.P., Hunter, Z.R., Aggarwal, A., Ewen, E.P., Masota, S., Lee, C., Santos, D.D., Hatjiharissi, E., Xu, L., Leleu, X., Tournilhac, O., Patterson, C.J., Manning, R., Branagan, A.R. & Morton, C.C. (2006) Characterization of familial Waldenström's macroglobulinemia. Annals of Oncology, 17, 488–494.
- Treon, S.P., Soumerai, J.D., Branagan, A.R., Hunter, Z.R., Patterson, C.J., Ioakimidis, L., Briccetti, F.M., Pasmantier, M., Zimbler, H., Cooper, R.B., Moore, M., Hill, J. 2nd, Rauch, A., Garbo, L., Chu, L., Chua, C., Nantel, S.H., Lovett, D.R., Boedeker, H., Sonneborn, H., Howard, J., Musto, P., Ciccarelli, B.T., Hatjiharissi, E. & Anderson, K.C. (2008) Thalidomide and rituximab in Waldenström macroglobulinemia. Blood, 112, 4452–4457.
- Treon, S.P., Soumerai, J.D., Branagan, A.R., Hunter, Z.R., Patterson, C.J., Ioakimidis, L., Chu, L., Musto, P., Baron, A.D., Nunnink, J.C., Kash, J.J., Terjanian, T.O., Hyman, P.M., Nawfel, E.L., Sharon, D.J., Munshi, N.C. & Anderson, K.C. (2009a) Lenalidomide and rituximab in Waldenström's macroglobulinemia. Clinical Cancer Research, 15, 355–360.
- Treon, S.P., Branagan, A.R., Ioakimidis, L., Soumerai, J.D., Patterson, C.J., Turnbull, B., Wasi, P., Emmanouilides, C., Frankel, S.R., Lister, A., Morel, P., Matous, J., Gregory, S.A. & Kimby, E. (2009b) Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia. Blood, 113, 3673–3678.
- Treon, S.P., Ioakimidis, L., Soumerai, J.D., Patterson, C.J., Sheehy, P., Nelson, M., Willen, M., Matous, J., Mattern, J. 2nd, Diener, J.G., Keogh, G.P., Myers, T.J., Boral, A., Birner, A., Esseltine, D.L. & Ghobrial, I.M. (2009c) Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05–180. Journal of Clinical Oncology, 27, 3830–3835.
- Treon, S.P., Yang, G., Hanzis, C., Ioakimidis, L., Verselis, S.J., Fox, E.A., Xu, L., Hunter, Z.R., Tseng, H., Manning, R.J., Patterson, C.J., Sheehy, P. & Turnbull, B. (2011a) Attainment of complete/very good partial response following rituximab-based therapy is an important determinant to progression-free survival, and is impacted by polymorphisms in FCGR3A in Waldenström macroglobulinaemia. British Journal of Haematology, 154, 223–228.
- Treon, S.P., Hanzis, C., Manning, R.J., Ioakimidis, L., Patterson, C.J., Hunter, Z.R., Sheehy, P. & Turnbull, B. (2011b) Maintenance rituximab is associated with improved clinical outcome in rituximab naive patients with Waldenström macroglobulinaemia who respond to a rituximab-containing regimen. British Journal of Haematology, 154, 357–362.
- Treon, S.P., Soumerai, J.D., Hunter, Z.R., Patterson, C.J., Ioakimidis, L., Kahl, B. & Boxer, M. (2011c) Long-term follow-up of symptomatic patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia treated with the anti-CD52 monoclonal antibody alemtuzumab. Blood, 118, 276–281.
- Treon, S.P., Hanzis, C., Tripsas, C., Ioakimidis, L., Patterson, C.J., Manning, R.J. & Sheehy, P. (2011d) Bendamustine therapy in patients with relapsed or refractory Waldenström's macroglobulinemia. Clinical Lymphoma, Myeloma & Leukemia, 11, 133–135.
- Treon, S.P., Xu, L., Yang, G., Zhou, Y., Liu, X., Cao, Y., Sheehy, P., Manning, R.J., Patterson, C.J., Tripsas, C., Arcaini, L., Pinkus, G.S., Rodig, S.J., Sohani, A.R., Harris, N.L., Laramie, J.M., Skifter, D.A., Lincoln, S.E. & Hunter, Z.R. (2012) MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. New England Journal of Medicine, 367, 826–833.
- Usmani, S., Sexton, R., Crowley, J. & Barlogie, B. (2011) Autologous stem cell transplantation as a care option in Waldenström's macroglobulinemia. Clinical Lymphoma, Myeloma & Leukemia, 11, 139–142.
- Varettoni, M., Tedeschi, A., Arcaini, L., Pascutto, C., Vismara, E., Orlandi, E., Ricci, F., Corso, A., Greco, A., Mangiacavalli, S., Lazzarino, M. & Morra, E. (2012) Risk of second cancers in Waldenström macroglobulinemia. Annals of Oncology, 23, 411–415.
- Wang, H., Chen, Y., Li, F., Delasalle, K., Wang, J., Alexanian, R., Kwak, L., Rustveld, L., Du, X.L. & Wang, M. (2012) Temporal and geographic variations of Waldenström macroglobulinemia incidence: a large population-based study. Cancer, 118, 3793–3800.
- Wechalekar, A.D., Lachmann, H.J., Goodman, H.J., Bradwell, A., Hawkins, P.N. & Gillmore, J.D. (2008) AL amyloidosis associated with IgM paraproteinemia: clinical profile and treatment outcome. Blood, 112, 4009–4016.
- Xu, L., Hunter, Z.R., Yang, G., Zhou, Y., Cao, Y., Liu, X., Morra, E., Trojani, A., Greco, A., Arcaini, L., Varettoni, M., Brown, J.R., Tai, Y.T., Anderson, K.C., Munshi, N.C., Patterson, C.J., Manning, R., Tripsas, C., Lindeman, N.I. & Treon, S.P. (2013) MYD88 L265P in Waldenström's macroglobulinemia, IgM monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific PCR. Blood, 121, 2051–2058.
Citing Literature
